for a Thank time very Good you at welcome, quarter third Scholar everyone. and Carmen. our business exciting you, Thank Rock. morning, joining update. It's
successful today's muscular financing, SAPPHIRE, of Phase registration atrophy our Financial heading and spinal the Chief I'm a Ted Officer. have With of the success Chief our to we study III Officer momentum call great XXXX. in and Myles, Operating end joined by on
business remarks start call the I For our questions. Ted morning, before up call provide for company with this a few and opening update I'll financial the closing will will and overview, provide a
we has time X, momentum dedication very Slide of our organization the that on on The deliver key execute all milestones schedule. created of ahead and quarter, the and throughout we shown had XXXX. The teams continue been building across on to or another As remarkable. commitment successful
approvals. next first XXXX QX follow, toward milestones submitting and regulatory great commercial job For the the of clinical the results in outstanding muscular in flawless the advance allows our SAPPHIRE This apitegromab execution important us to atrophy, in U.S. us Europe keeps program did high an data out XXXX, lead and of us spinal on to have team in launch quality, to and the successful with in skill, with QX assuming enabling report speed delivering the to BLA early with track MAA our October.
than our highly we ahead cadence to II research in now with a us SRK-XXX, In disorders. planned, nonclinical team the of proof-of-concept schedule, selective Phase earlier and continues targeting novel, top out with EMBRAZE program positioning addition, line of QX obesity informative Similarly, cardiometabolic completed results data for XXXX. enrollment apitegromab, to report deliver of anti-myostatin our steady
team In enable addition take industry addition to advantage as to has our produced Beth of focused investment veteran management a products. opportunities potential Beth to guide Chief of an high-value in our Business help execution, Shafer. expanded partnering and joined us decisions September who full validated platform with the our Officer pipeline to our we robust is of that
X. Slide to Turning
Before third quarter provide results, want of I here. we as reminder why detail our with start to to I more a are
want activities made can Motor the create is turning with improvement clear or for that those it a designed activities independence feeding new be they Functional means basic Our daily that order a specifically to seeking, gaining in made bed scale muscle and to like strength clear, operating it Hammersmith for purpose motorized is more. living achieved Liza X- for ], muscle on maintain what yourself, maintained X-point When such a SMA as Liza possibilities SMA. in everything. More asked who muscle, with to wheelchair, was [ or Scale, function she
Slide to X. Now
of demonstrated despite lost the on significant those versus III with Scale statistically function Functional point measured as of standard Phase primary by the the met placebo pivotal week SAPPHIRE This X.X early As endpoint standard by our announced we receiving study of improvement function measured SMA-specific gold increasing with standard Scale care apitegromab compared October, care a improvement a patients was gaining as with plus placebo in apitegromab Hammersmith benefit XX. of at meaningful clinically the to of care. being plus p-value standard placebo motor Motor function, and X.XXXX.
Patients apitegromab receiving while Hammersmith
SAPPHIRE of patients showed scores. their or consistency of effect apitegromab care, With transformative a of already greater with broad in X-point standard were X groups age to Importantly, XX Hammersmith who SMA tolerability, safety years in XX% receiving based TOPAZ improvement was population.
Further, additional consistent across seen SMA and apitegromab favorable demonstrated achieving and study.
The apitegromab's on to treatment our safety clinical observed of selective doses in of an to profile profile activity Phase confirmed over profile, the apitegromab's respect is in which X approach established consistent safety blocking myostatin. II highly with safety with
that with and the for it their physicians. these of caregivers We We means standard collectively are the thrilled believe to families, a data new become potential care community, SMA. part results show patients, what apitegromab SMA has these of and in
to Despite our the from helpful representing targeting inherent SMA.
This line nature in represents understand the results of it SMA graph the of risk CHERISH-SHINE those over X the availability with year. into over The Turning motor at still progressive randomized standard context, for put function the of individuals to early referred the scores like the of trajectory of was losing receiving protein, this the approved group. patients to time the at Liza dose of to time SMN for X. Cure orange given illustrated normal study meeting is those June are Slide To function treatment. care nusinersen trajectory nusinersen-treated Hammersmith as therapies
As in of of loss for their time nusinersen were the clearly a time X in similar declining progressive starting After of of there's approximately the there's function. this further standard function treatment, SAPPHIRE, motor X of motor nusinersen is on treatment standard where with point shown, continued treatment phase of represents of care year box duration shaded years of improvement where however, the X purple a period treatment after care. of median a patients function those treatment by period SAPPHIRE with despite duration improved the on journey plateau the nusinersen, in while the per terms to treatment the first years motor that no therapy.
The for enrolled followed
These at line treatment the displays over benefit visit. a course by graphs over function period. the motor treatment to change apitegromab Slide the Hammersmith articulate affects how take in baseline the beautifully Now of apitegromab scores time, from look of XX
see, being apitegromab pre-specified By illustrated Slide course, decreased scores you Hammersmith between by from improved of plot nusinersen X.X data shown can widens analyses in separation X first of placebo about apitegromab on year apitegromab. by disease on after X by and loss the a The losing those on period, per end of the that indicated point similar scores on on as function change the of apitegromab in The as patients treatment years early on long-term contrast, treatment.
There's baseline results difference forest function XX. the adding standard the post-baseline with of early placebo. minus underscoring the points, a effect weeks, the As strength to care, assessment. the of of the to is of the all gaining from despite for X the
the is to These shown, age and As the across strength results. analyses analyses there of apitegromab, across with showing all groups. improvement consistency speak favoring our and across doses robustness including
the for the population believe of chronic Slide function the lives consistency versus functional treatment those seen to SMA.
We to disease on apitegromab on strength improvements This based urgency losing for top ability in with standard broad and to to finalize of profile Moving magnitude XX, is seen supported with for To patients age applications with suitable with of we X-point the for XX.X% is living quarter of are first gaining regulatory improvement, on with across years those the working apitegromab extraordinary of a a on MAA groups SMA the XXXX. improvement experience underscore safety the of the on in well-tolerated to XX. X alter of results efficacy care. the all impact demonstrate from XX% safety potential SMA profound by course placebo. and the improvement apitegromab function of X submit of further and achieving more with and SAPPHIRE Again, we see SAPPHIRE transformative than our BLA of
The Now rapid moving approvals Slide and our has impact tirzepatide on positive cardiometabolic to obesity. on with XX. living semaglutide and of had program those very adoption recent
associated However, muscle the these has is highly that of effective significant emerged a lean loss issue key treatments. mass with
metabolism preserving receptor homeostasis, obesity and of GLP-X muscle weight selective anti-myostatin Given lean appropriate with glucose We and in the essential approach management. living. muscle preserve see levels mass SRK-XXX, lean healthy our to of muscle the maintaining of highly promote working the role to as in novel can believe healthy our muscle used SRK-XXX and the lean the when to treatment part important energy midyear-XXXX. innovation are We IND agonist next for is with submit wave mass of targeted plays
during comprehensive and loss, to glucose promising and rationale evidence, we've lean XX. improvement a receptor an SRK-XXX. including preservation fat gain lean of fat mass of beyond agonist-induced potency demonstrated alone, mass increase receptor fasting recently, most strong increase withdrawal, designed in SRK-XXX. GLP-X to-date, GLP-X an demonstrating And to mass We treatment agonist receptor nonclinical following lean attenuation program and antibody Now Slide greater scientific lowered nonclinical and compared weight in agonist and metformin mass in with regain with GLP-X anti-ACTRX following mass
the solution management. Turning profile preserving we believe an obesity have healthy risk-benefit of long-term We into for to potential with entered mass area as XX. to weight muscle Slide elegant we lean a attractive
negative right myostatin, and growth of have muscle is of inhibition a to We function. regulator promote target muscle the known
loss potential have minimizes myostatin SAPPHIRE, favorable and and of given of further, results to and Ted function.
And unwanted provide form We motor a latent the preserving for financial risk a and update. a of lean has pre- our highly in supports durability approach to selective toxicities improvement our demonstrating will of benefit the weight targeting potential profile.
I Ted? now approach invite validation the mass in the improve business
